Evidence map›Paper›PMID 37515631›Full record

ArticleLa Radiologia medica2023

Pancreatic cancer detection with a non-contrast MR protocol: is it reliable?

Francesca Maio, Vincenzo Pasqualino, Luca Bertana, Silvia Venturini, Valeria Cantoni, Michele Fusaro, Giovanni Morana

Abstract read
In one paragraph

Article in La Radiologia medica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Imaging of the Liver and Pancreas: The Added Value of MRI.Diagnostics (Basel, Switzerland) · 2024
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Francesca MaioDepartment of Advanced Biomedical Sciences, Federico II University, Via Pansini 5, 80131, Naples, Italy. francescamaio9@gmail.com.ORCID http://orcid.org/0000-0003-0395-3969
Vincenzo PasqualinoDepartment of Radiology, Padua University, Via 8 Febbraio 1848, 2, 35122, Padua, Italy.
Luca BertanaDepartment of Radiology, General Hospital Ca' Foncello, Piazzale dell' Ospedale 1, 31100, Treviso, Italy.
Silvia VenturiniDepartment of Radiology, General Hospital Ca' Foncello, Piazzale dell' Ospedale 1, 31100, Treviso, Italy.
Valeria CantoniDepartment of Advanced Biomedical Sciences, Federico II University, Via Pansini 5, 80131, Naples, Italy.
Michele FusaroDepartment of Radiology, General Hospital Ca' Foncello, Piazzale dell' Ospedale 1, 31100, Treviso, Italy.
Giovanni MoranaDepartment of Radiology, General Hospital Ca' Foncello, Piazzale dell' Ospedale 1, 31100, Treviso, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe pancreatic cancer (PC) is the 4th leading cancer-related death, becoming the second one by 2030, with a 5 year survival rate of 8%. Considering its increased incidence in high-risk categories compared to the general population, we aimed to validate a non-contrast MR protocol, to detect PC in its earliest phase, which could be suitable as a screening tool in high-risk patients. MATERIALS AND

methodsIn this retrospective study, we selected 200 patients (> 40 years) from our radiological database, which performed upper abdominal MRI between 2012 and 2017. 100 were negative for pancreatic lesions and 100 positive for pancreatic lesion (< 30 mm). The latter group included: 40 PDAC (pancreatic adenocarcinoma), 42 BD-IPMN (Branch Duct- Intraductal Papillary Mucinous Neoplasm), 10 PNET(pancreatic neuroendocrine tumor), 4 SCN(serous cystic neoplasm), 3 IPS(intrapancreatic spleen), 1 MCN(mucinous cystic neoplasm). Three readers (R1, R2 and R3) with a high, medium and low experience, respectively, analysed, first, the non-contrast MR sequences (single-shot T2w breath-hold, GE T1w FS, DWI and 2D/3D MRCP), and then the standard MR protocol, independently, randomly and anonymously. Readers identified or excluded the presence of pancreatic lesion, in both reading sessions. These results were compared with the histopathological diagnosis, and then divided into 3 different classes of lesions: all lesions, pancreatic adenocarcinoma and solid lesion. Mcnemar's test was used to compare the results. The inter-observer agreement was determined according to the kappa statistic in both protocols, and then the inter-protocol agreement was calculated.

resultsThe non-contrast MR protocol has reached statistical parameters values ranging between 83% in SE (sensitivity) by R3 and 99% in NPV (negative predictive value) by R1. The standard MR protocol has reported slight increasing statistical parameters compared to those of the proposed one. However, there are not significant statistical differences between the both protocols. The proposed non-contrast MR protocol has reported the highest NPVs in the PDAC group detection (R1: 99%, R2: 99%, R3: 98%). In all groups of lesions, the agreement between the two protocols was excellent for each Reader ranging from 96 to 98%.

conclusionThe proposed non-contrast MR protocol showed high PC detection values and a time execution ≤ 20 min. Therefore, it can be proposed as a screening tool in high-risk patients.

Indexed as

AdenocarcinomaCarcinoma, Pancreatic DuctalPancreatic NeoplasmsHumansMagnetic Resonance ImagingRetrospective StudiesInter observer agreementMRCPPancreatic cancerPancreatic lesionsPatientsRetrospective study

Identifiers

PMID37515631
PMCPMC10474201

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.